Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Abstract Background Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect evidence of some aspects of the safety and...

Descrición completa

Detalles Bibliográficos

Principais autores:	Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martínez
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-09-01
Series:	Annals of General Psychiatry
Assuntos:	Schizophrenia Risperidone Matching-adjusted indirect comparison MAIC Extrapyramidal symptom Anticholinergics
Acceso en liña:	https://doi.org/10.1186/s12991-023-00464-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!